Actively Recruiting
Phase III Study with an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
Led by CUTISS AG · Updated on 2025-01-28
70
Participants Needed
1
Research Sites
185 weeks
Total Duration
On this page
Sponsors
C
CUTISS AG
Lead Sponsor
R
RCTs
Collaborating Sponsor
AI-Summary
What this Trial Is About
This multicentre phase III clinical trial will target adults and adolescents of 12 years and older with severe burns to confirm the efficacy and functionality of denovoSkin™ in achieving wound closure and reducing scarring in patients with deep partial and full-thickness burns as compared to split-thickness skin.
CONDITIONS
Official Title
Phase III Study with an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with deep partial or full-thickness thermal burns covering 20% or more of total body surface area (TBSA) requiring excision and standard treatment
- Patients aged 12 years or older
- Signed informed consent from patient or legally authorized representative
You will not qualify if you...
- Burn wounds only on the head and neck
- Patients who can have all areas grafted in a single surgery earlier than denovoSkin14 manufacturing allows
- Active infection with hepatitis B, hepatitis C, HIV, or Treponema pallidum
- Medical conditions that may significantly delay wound healing, including high HbA1c or systemic skin/connective tissue diseases
- Pre-existing blood clotting disorders outside normal ranges
- History of severe allergic reactions to amphotericin B, gentamicin, penicillin, streptomycin, or bovine collagen derivatives
- Previous treatment with denovoSkin14
- Participation in another clinical trial within 60 days (for monoclonal antibodies) or 30 days (for other investigational products)
- Unable or unwilling to follow study procedures
- Pregnant or breastfeeding women
- Women of childbearing potential not using highly effective birth control and unwilling to undergo pregnancy testing
- Investigator or related personnel involved in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rode Kruis Ziekenhuis
Beverwijk, Netherlands, 1942
Actively Recruiting
Research Team
D
Daniela Marino
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here